Key facts
Reacts with:Human
Product details:
GITR Antibody Panel ab252195 contains multiple trial-sized versions of anti-human antibody clones against GITR, specifically selected for high performance in IHC. This panel contains 3 recombinant rabbit monoclonal antibodies against human GITR. They are provided in trial sizes to allow you to easily evaluate which is the best GITR antibody for your IHC research assay needs.
For guidelines on how to use each antibody within the panel, please consult the individual datasheet for each antibody.
Panel contains:
- Rabbit monoclonal [CAL52] to GITR (20 μL)
ab237713
- Rabbit monoclonal [CAL8] to GITR (20 μL)
ab237714
- Rabbit monoclonal [EPR20566] to GITR (20 μL)
ab223841
Explore our range of antibody sample panels designed to provide you with a variety of trial-size antibodies in a convenient and cost-effective format.
Carrier-free formulations of our recombinant antibodies are also available for easy conjugation to labels of your choice and for multiplex applications. Use our intuitive search and select carrier-free or your label of choice. For bespoke conjugations or large volumes email
[email protected].
Properties and Storage Information:
Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-+4°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
GITR also known as TNFRSF18 is a 241 amino acid protein with a mass of approximately 27 kDa. It belongs to the tumor necrosis factor receptor superfamily. GITR is highly expressed on activated T cells and regulatory T cells (Tregs). The gene encoding GITR is located on chromosome 1 in humans. High surface expression is also observed in immune tissues such as the thymus spleen and lymph nodes playing an important role in immune responses.
Biological function summary
GITR acts as a costimulatory molecule that enhances T cell activation and proliferation. It does not function as part of a complex but interacts directly with ligand GITRL triggering downstream signaling cascades. This interaction is key in the modulation of immune responses notably in enhancing the activity of effector T cells and regulating Treg functions. Activation of GITR can reduce Treg-mediated suppression leading to enhanced immune responses.
Pathways
The mechanistic role of GITR involves NF-kB and MAPK signaling pathways. Through these GITR impacts immune responses by stimulating the production of cytokines and promoting cell survival and proliferation. GITR signaling intersects with pathways involving proteins such as NF-kB further integrating with the immune system's regulation crescendo.
GITR appears to play a role in autoimmune conditions like rheumatoid arthritis and potential cancer immunotherapy. In autoimmune diseases GITR modulates immune activity influencing the balance between inhibition and activation of T cells. In oncology GITR targeting aims to enhance immune responses against tumors. Through these conditions GITR shows connections to proteins such as CTLA-4 which also contributes to immune regulatory processes.
